Business Segments · Net (loss) income

Business Segments — Net (loss) income

Roivant Sciences Business Segments — Net (loss) income decreased by 88.9% to -$313.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 365.7%, from $118.08M to -$313.70M. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ2 2023
Last reportedQ4 2025
Rolls up toNet Income

How to read this metric

Higher net income indicates strong operational performance and commercial success, while net losses may indicate high R&D investment or underperforming commercial assets.

Detailed definition

This represents the bottom-line financial performance of a specific reportable segment after all operating expenses, int...

Peer comparison

Comparable to segment operating profit or segment net income reported by other biopharmaceutical companies with multiple business lines.

Metric ID: roiv_segment_reportable_segment_net_loss_income

Historical Data

9 periods
 Q2 '23Q3 '23Q4 '23Q1 '24Q3 '24Q4 '24Q1 '25Q3 '25Q4 '25
Value$1.06B$1.06B$1.06B$1.06B-$279.92M$118.08M-$252.38M-$166.04M-$313.70M
QoQ Change+0.0%+0.0%+0.0%-126.5%+142.2%-313.7%+34.2%-88.9%
YoY Change-126.5%-88.8%-123.9%+40.7%-365.7%
Range-$313.70M$1.06B
CAGR-45.5%
Avg YoY Growth-132.8%
Median YoY Growth-123.9%

Frequently Asked Questions

What is Roivant Sciences's business segments — net (loss) income?
Roivant Sciences (ROIV) reported business segments — net (loss) income of -$313.70M in Q4 2025.
How has Roivant Sciences's business segments — net (loss) income changed year-over-year?
Roivant Sciences's business segments — net (loss) income decreased by 365.7% year-over-year, from $118.08M to -$313.70M.
What does business segments — net (loss) income mean?
The total profit or loss generated by a specific business segment.